Vaxcyte Inc. Common Stock (PCVX)
Stock · NASDAQ · Health Care
$63.61as of 10/16/2026
Price chart
Active signals
Support level
$58.78
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
PCVX Signal Track Record
How signals performed across all stocks →What PCVX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +3.4% | 57% | October 5, 2026 |
| Bollinger Band Breakout | 24 | +2.6% | 54% | October 5, 2026 |
| Bollinger Band Breakdown | 22 | -0.0% | 50% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +7.4% | 78% | June 16, 2026 |
| Any 20-session window (baseline) | +2.1% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PCVX
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigati…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 507
- Website
- vaxcyte.com/
Fundamentals
- 1-day range
- $62.54$65.34
- Market cap
- $8.50B
- P/E (trailing)
- —
- P/E (forward)
- -8.90
- EPS (trailing)
- $-7.64
- Dividend yield
- —
- Beta
- 1.31
- Avg. volume
- 1.84M
52-week range
$39.87$90.75
Next earnings: November 3, 2026 · EPS estimate $-2.11confirmed
Forecasts
10 analyst ratings
Buy 88%
Hold 12%
Sell 0%
1-year price forecast
High
$163
+156.2%
Median
$121
+90.2%
Low
$75
+17.9%
Vaxcyte Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PCVXVaxcyte Inc. Common Stock$63.62▼ 2.53%Market cap $8.50BP/E —$39.87$90.75
- QGENQiagen N.V. Common Shares$46.13▼ 0.09%Market cap $8.60BP/E 22.92$32.53$57.82
- KYMRKymera Therapeutics Inc. Common Stock$104.78▼ 3.11%Market cap $8.75BP/E —$55.26$130.05
- IMVTImmunovant Inc. Common Stock$26.73▼ 2.84%Market cap $8.20BP/E —$16.6$45.42
- RGENRepligen Corporation Common Stock$175.42▼ 4.75%Market cap $9.00BP/E 244.54$100.99$198.87
- IBRXImmunityBio Inc. Common Stock$9.18▼ 8.20%Market cap $7.76BP/E —$1.95$12.43
- KRYSKrystal Biotech Inc. Common Stock$316.58▼ 4.07%Market cap $9.55BP/E 40.85$181.44$382.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PCVX Vaxcyte Inc. Common Stock | $8.50B | — | $63.62 | ▼ 2.53% | $39.87$90.75 |
| QGEN Qiagen N.V. Common Shares | $8.60B | 22.92 | $46.13 | ▼ 0.09% | $32.53$57.82 |
| KYMR Kymera Therapeutics Inc. Common Stock | $8.75B | — | $104.78 | ▼ 3.11% | $55.26$130.05 |
| IMVT Immunovant Inc. Common Stock | $8.20B | — | $26.73 | ▼ 2.84% | $16.6$45.42 |
| RGEN Repligen Corporation Common Stock | $9.00B | 244.54 | $175.42 | ▼ 4.75% | $100.99$198.87 |
| IBRX ImmunityBio Inc. Common Stock | $7.76B | — | $9.18 | ▼ 8.20% | $1.95$12.43 |
| KRYS Krystal Biotech Inc. Common Stock | $9.55B | 40.85 | $316.58 | ▼ 4.07% | $181.44$382.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Targetbenzinga · 10/12/2026
- BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine PushYahoo · 10/10/2026
- Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior NotesYahoo · 10/9/2026
- A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock RallyBenzinga · 10/9/2026
- Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York TimesBenzinga · 10/9/2026
- Why Vaxcyte (PCVX) Is Getting Attention AgainYahoo · 10/8/2026
- 'Russia Denies Report of Second Case of Illness in Siberia' - BloombergBenzinga · 10/8/2026
- Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesYahoo · 10/7/2026
- Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest LosersYahoo · 10/6/2026
Insider Activity
Insider Actions →Acquired
180.1K
Disposed
79.2K
- Elvia Cowan · October 5, 2026 · Option Exercise19.0K @ $25.92
- Elvia Cowan · October 5, 2026 · Sale19.0K @ $86.74
- Jim Wassil · October 5, 2026 · Option Exercise18.0K @ $5.35
- Jim Wassil · October 5, 2026 · Sale18.0K @ $86.74
- Jim Wassil · October 1, 2026 · Option Exercise2.3K @ $5.35
- Jim Wassil · October 1, 2026 · Sale95 @ $57.09
- Jim Wassil · October 1, 2026 · Sale2.2K @ $56.65
- Jim Wassil · September 9, 2026 · Sale1.3K @ $59.52
- Harpreet S. Dhaliwal · September 8, 2026 · Tax Withholding7.7K @ $60.36
- Jim Wassil · September 8, 2026 · Tax Withholding5.5K @ $60.36
- Grant Pickering · September 8, 2026 · Tax Withholding17.1K @ $60.36
- Andrew Guggenhime · September 8, 2026 · Tax Withholding7.2K @ $60.36
- Elvia Cowan · September 8, 2026 · Tax Withholding1.3K @ $60.36
- Jodar Luis · September 4, 2026 · Grant88.3K
- Jodar Luis · September 4, 2026 · Grant52.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 156.84M
- Total value held
- $8.26B
- Institutional holders
- 330
Top holders this quarter
- Unknown16.58M
- Unknown16.49M
- Unknown12.13M
- Unknown11.47M
- Unknown10.97M
- Unknown6.27M
- Unknown5.61M
- Unknown4.79M
- Unknown4.44M
- Unknown4.30M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints
Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints. Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.